Chemical formula: C₁₅H₂₂N₂O Molecular mass: 246.354 g/mol PubChem compound: 65833
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06AX17 | Milnacipran | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| FETZIMA Extended release capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| SAVELLA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Milnacipran is an active ingredient of these brands:
Austria (AT)
Canada (CA)
Estonia (EE)
Hong Kong (HK)
Japan (JP)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
